-
10:51:32 AM

GERN Stock News

06/02/23 3:30 PM
Nasdaq : GERN
acquisitionclinical trial
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
Geron Corporation, a late-stage clinical biopharmaceutical company, announced a presentation reporting durable continuous transfusion independence with imetelstat, the Company’ s first-in-class telomerase inhibitor, in IMerge Phase 3 lower risk MDS patients. These data were presented today at the American Society of Clinical Oncology Annual Meeting...
RHEA-AI
neutral
05/25/23 5:02 PM
Nasdaq : GERN
acquisitionclinical trial
Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
Geron Corporation, a late-stage clinical biopharmaceutical company, today announced acceptance of its IMerge Phase 3 abstract as an oral presentation at the upcoming 2023 American Society of Clinical Oncology Annual Meeting. This abstract describes statistically significant positive efficacy and safety data from the pivotal IMerge Phase 3 clinical...
RHEA-AI
neutral
05/11/23 10:02 AM
Nasdaq : GERN
conferencesacquisitionclinical trial
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
Geron Corporation, a late-stage clinical biopharmaceutical company, today announced that five abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted at the European Hematology Association Annual Meeting taking place from June 8-11, 2023 in Frankfurt, Germany and virtually. The three EHA abstracts on IMerge Phase 3...
RHEA-AI
neutral
05/11/23 8:00 AM
Nasdaq : GERN
earnings
Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights
“We believe that imetelstat has a compelling commercial value proposition and is well-positioned to become a standard of care in lower risk MDS, based on unprecedented broad durability of transfusion independence in the IMerge Phase 3 trial and high unmet need in this patient population,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.“ We are on...
RHEA-AI
neutral
04/26/23 10:05 AM
Nasdaq : GERN
clinical trial
Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial
Geron Corporation, a late-stage clinical biopharmaceutical company, today announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’ s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes, was accepted for oral presentation at the 2023 American Society of Clinical Oncology Annual...
RHEA-AI
neutral